首页>
外国专利>
Anhydrate-Free Polymorphically Pure Micronized Crystalline Brexpiprazole Di-Hydrate For Use In Intramuscular Injectable Sustained Release Formulations
Anhydrate-Free Polymorphically Pure Micronized Crystalline Brexpiprazole Di-Hydrate For Use In Intramuscular Injectable Sustained Release Formulations
展开▼
机译:用于肌内注射缓释制剂的无水多晶型纯净微粉化溴乙哌唑二水合物
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention relates to a brexpiprazole dihydrate crystalline form having a particle size distribution of d50 of at most 10 μm and less than 5% w/w of brexpiprazole anhydrate. The present invention also relates to a process for preparing this brexpiprazole dihydrate crystalline form and to pharmaceutical compositions thereof. The present invention also relates to a process for determining the absence of brexpiprazole anhydrate in this brexpiprazole dihydrate crystalline form. This brexpiprazole dihydrate crystalline form is used for the preparation of pharmaceutical compositions having delayed release properties upon intramuscular injection.
展开▼
机译:brexpiprazole二水合物结晶形式本发明涉及一种具有d50的粒径分布至多10μm和小于5%w / w brexpiprazole anhydrate的溴化萘二甲酸结晶形式。本发明还涉及一种制备该brexpiprazole二水合物结晶形式的方法及其药物组合物。本发明还涉及一种确定该brexpiprazole二水合物晶体形式不存在brexpiprazole anhydrate的方法。该brexpiprazole二水合物结晶形式用于制备在肌肉内注射时具有延迟释放特性的药物组合物。
展开▼